India’s MSN Laboratories Pvt. Ltd. has kicked off 2021 by launching four generics after receiving a raft of US Food and Drug Administration approvals during the first quarter. Through its US affiliate, Novadoz, the company has launched albendazole 200mg tablets; droxidopa 100mg, 200mg, 300mg capsules; deferasirox granules in 180mg and 360mg sachets; and pregabalin extended-release tablets in 82.5mg, 165mg and 330mg strengths.
MSN’s Novadoz Makes Multiple US Launches
Company Commences Shipping Of Albendazole, Droxidopa, Deferasirox And Pregabalin
India’s MSN Labs has kicked off the year by launching four recently-approved generics in the US through affiliate Novadoz, including albendazole, droxidopa, deferasirox and pregabalin. The company says it is preparing a “deep pipeline” of launches for the next 10 years.
